<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>We have previously shown the neuroprotective effect of atypical <z:chebi fb="0" ids="35476">antipsychotic agents</z:chebi> by experimental <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>However the impact of their high dose related side effects on their low dosage related neuroprotectivity is still unknown.We evaluated the possible neuroprotective effects of high dose <z:chebi fb="0" ids="7735">olanzapine</z:chebi> (10mg/kg) treatment on ischemic brain injury 24 hr after permanent <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain><z:chebi fb="0" ids="7735">Olanzapine</z:chebi> showed neither a neuroprotective nor a neurotoxic effect after focal <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo> </plain></SENT>
<SENT sid="3" pm="."><plain>This finding could suggest that dose related side effect of <z:chebi fb="0" ids="7735">olanzapine</z:chebi> could involve a restriction of its neuroprotective effect unlike lower doses that have been reported to have neuroprotective effect </plain></SENT>
</text></document>